Processa Pharmaceuticals, Inc. Deferred Federal Income Tax Expense (Benefit)
Processa Pharmaceuticals, Inc. (PCSA) reported Deferred Federal Income Tax Expense (Benefit) of -$5.89 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2023-03-30
- Processa Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2022 was -$5.89M.
- Processa Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2021 was -$2.85M.
- Processa Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2020 was -$3.07M.
- Processa Pharmaceuticals, Inc. deferred federal income tax expense (benefit) for fiscal 2019 was -$1.04M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2022-12-31 | -$5.89M 10-K · filed 2023-03-30 |
| 2021-12-31 | -$2.85M 10-K · filed 2023-03-30 |
| 2020-12-31 | -$3.07M 10-K · filed 2022-03-30 |
| 2019-12-31 | -$1.04M 10-K · filed 2021-03-25 |
| 2018-12-31 | -$940.51K 10-K · filed 2020-03-06 |
| 2017-12-31 | -$116.78K 10-K/A · filed 2019-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |